Dr. Bruce Freeman is Irwin Fridovich Distinguished Professor and Chair of the Department of Pharmacology and Chemical Biology at the University of Pittsburgh. Prior to this position, he was a professor and director of the Center for Free Radical Biology at the University of Alabama at Birmingham. Before that, he trained at the University of California and Duke University. He has published ~300 peer reviewed articles and ~70 reviews/chapters. He and his team study eukaryotic cell production and actions of reactive inflammatory and signaling mediators, with the intent to develop targeted therapies to treat inflammatory, metabolic and cell proliferation-based disorders. His laboratory pioneered the concept that nitric oxide has cell signaling and pathogenic actions modulated by partially reduced oxygen species. They now focus on redox reaction-induced post-translational protein modification responses that impact the regulation of cell function. These precepts and synthetic homologs of endogenous mediators they have discovered are now being translated into clinical practice. Complexa, Inc. has licensed related intellectual property and, after five Phase 1 safety trials of IV and oral drug formulations, Phase 2 trials are presently evaluating the therapeutic actions of small molecule nitroalkenes in chronic renal, cardiovascular and pulmonary diseases. Freeman and colleagues have also licensed their recent intellectual property related to composition of matter and methods of treatment of cell proliferation-related disorders to Creegh Pharmaceuticals, with the intent of treating a) drug and immune-therapy-resistant cancers and b) co-morbidities of obesity